-+ 0.00%
-+ 0.00%
-+ 0.00%

Candel Therapeutics Q2 EPS $(0.52) Misses $(0.23) Estimate

Benzinga·08/13/2026 12:47:03
Listen to the news
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.23) by 126.09 percent. This is a 477.78 percent decrease over losses of $(0.09) per share from the same period last year.